Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).
cellular invasion
cutaneous squamous-cell carcinoma
immunohistochemical markers
inflammatory infiltrate
skin cancer staging
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
27
12
2021
accepted:
18
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
ppublish
Résumé
Non-melanoma skin cancer (NMSC) is the most common type of neoplasm affecting Caucasian individuals, with squamous-cell carcinoma (cSCC) being the second most common type of NMSC after basal-cell carcinoma. The immunohistochemical study of cSCC is of particular importance, especially for the diagnosis of its rare forms, for which accurate and early diagnosis is crucial for survival. In the present review of the literature, the potentially significant value of immunohistochemical markers were highlighted to more accurately assess the biological behaviour, the prognosis of cSCC and to optimize case management. The immunohistochemical markers were classified from a pathophysiological point of view in order to present the mechanism by which carcinogenesis occurs with its subsequent evolution and therefore, to develop a more accurate novel risk staging criteria for this type of neoplasm.
Identifiants
pubmed: 35495612
doi: 10.3892/etm.2022.11308
pii: ETM-23-6-11308
pmc: PMC9019737
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
383Informations de copyright
Copyright: © Bălășescu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Curr Oncol. 2020 Aug;27(4):e399-e407
pubmed: 32905333
Cancers (Basel). 2022 Jan 13;14(2):
pubmed: 35053539
J Histotechnol. 2020 Sep;43(3):147-152
pubmed: 32496961
Br J Dermatol. 2018 Aug;179(2):405-412
pubmed: 29479687
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2128-35
pubmed: 25845701
Br J Dermatol. 2015 Jan;172(1):111-9
pubmed: 24975674
J Cutan Pathol. 2006 Jun;33(6):413-7
pubmed: 16776716
JAMA Dermatol. 2016 Mar;152(3):305-11
pubmed: 26560495
Ann Dermatol. 2013 Nov;25(4):515-7
pubmed: 24371410
J Clin Med. 2019 Jul 24;8(8):
pubmed: 31344926
J Am Acad Dermatol. 2019 Mar;80(3):626-632.e1
pubmed: 30359624
Transl Oncol. 2020 Jun;13(6):100773
pubmed: 32334405
Am J Dermatopathol. 2014 Oct;36(10):807-11
pubmed: 24999547
Br J Cancer. 2008 Apr 8;98(7):1274-84
pubmed: 18349846
JAMA Dermatol. 2019 Jul 1;155(7):819-825
pubmed: 30969315
Genes Dev. 2013 Oct 15;27(20):2192-206
pubmed: 24142872
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Br J Dermatol. 2017 May;176(5):1279-1287
pubmed: 27510450
Exp Cell Res. 2017 Sep 1;358(1):78-85
pubmed: 28412244
Exp Dermatol. 2017 Sep;26(9):771-777
pubmed: 27992079
J Cutan Pathol. 2009 May;36(5):543-7
pubmed: 19476522
J Skin Cancer. 2011;2011:420796
pubmed: 21773035
Oncoimmunology. 2016 Jan 13;5(4):e1119356
pubmed: 27141405
Clin Lab Med. 2017 Sep;37(3):503-525
pubmed: 28802498
Exp Toxicol Pathol. 1996 Feb;48(2-3):175-81
pubmed: 8672872
Zentralbl Gynakol. 2002 Nov;124(11):497-505
pubmed: 12796842
Br J Dermatol. 2009 Dec;161(6):1262-9
pubmed: 19663878
Oncol Lett. 2020 Mar;19(3):2133-2140
pubmed: 32194711
J Cutan Pathol. 2014 Nov;41(11):831-8
pubmed: 25263756
Dermatology. 2016;232(5):558-565
pubmed: 27875814
J Invest Dermatol. 2011 Jun;131(6):1322-30
pubmed: 21307877
J Am Acad Dermatol. 2012 Dec;67(6):1310-8
pubmed: 22521203
Br J Dermatol. 2011 Apr;164(4):696-711
pubmed: 21128907
J Cutan Pathol. 2009 Jun;36(6):668-74
pubmed: 19515046
Int J Clin Exp Pathol. 2008 Mar 07;1(6):524-30
pubmed: 18787630
Rom J Morphol Embryol. 2015;56(2 Suppl):665-70
pubmed: 26429157
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
J Cutan Pathol. 2014 Nov;41(11):839-45
pubmed: 25263848
Am J Dermatopathol. 2008 Jun;30(3):228-32
pubmed: 18496422
JAMA Dermatol. 2018 Apr 1;154(4):428-434
pubmed: 29516080
Histopathology. 2009 Jul;55(1):67-76
pubmed: 19614769
J Dermatol Sci. 2013 Nov;72(2):93-102
pubmed: 23928229
J Am Acad Dermatol. 2020 Apr;82(4):846-853
pubmed: 31437542
Oncotarget. 2017 Jul 11;8(28):45825-45836
pubmed: 28526809
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Cancer Res. 2007 May 1;67(9):4227-35
pubmed: 17483334
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
J Cutan Pathol. 2008 Apr;35(4):353-7
pubmed: 18333895
Rom J Morphol Embryol. 2016;57(2 Suppl):691-696
pubmed: 27833960
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3908-17
pubmed: 25120767
Clinics (Sao Paulo). 2011;66(3):465-8
pubmed: 21552674
Br J Dermatol. 2014 Nov;171(5):1014-21
pubmed: 24628329
Head Neck. 2019 May;41(5):1290-1296
pubmed: 30537291
Oncotarget. 2018 Feb 22;9(18):14552-14566
pubmed: 29581863
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
Dermatol Surg. 2006 Feb;32(2):177-83
pubmed: 16442036
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34
pubmed: 20490631
Actas Dermosifiliogr (Engl Ed). 2020 Apr;111(3):261-262
pubmed: 31980128
Curr Opin Immunol. 2007 Apr;19(2):203-8
pubmed: 17292599
J Skin Cancer. 2011;2011:210813
pubmed: 21234325